Sandoz' Sandostatin (octreotide)
Executive Summary
Supplemental NDA filed Nov. 24 for acromegaly, a growth disorder that affects approximately 15,000 in the U.S. Clinical trial results demonstrated reduction in growth hormone secretion to normal levels in "approximately 50%" of patients with acromegaly and reduced levels of IGF-1, a growth factor that mediates growth hormone, in 50%-60% of patients, Sandoz reports. Sandostatin has been available in the U.S. since 1988 for chronic diarrhea associated with carcinoid tumors and VIPomas.